Skip to main content

Market Overview

BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica

BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
  • BeiGene Ltd (NASDAQ: BGNErevealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (NYSE: JNJ) Imbruvica (ibrutinib) for relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • In the study, Brukinsa shrunk tumors in more patients than Imbruvica did while causing fewer incidents of a dangerous heart side effect.
  • Data were unveiled at the European Hematology Association virtual congress.
  • Brukinsa triggered an overall response in 78.3% of patients, significantly more than Imbruvica’s 62.5% after a median of 15 months of follow-up.
  • But when analyzed by an independent data review committee, the BeiGene drug’s efficacy edge narrowly missed the statistical significance bar, with the response rates at 76.3% and 64.4% for Brukinsa and Imbruvica, respectively.
  • At the one-year mark, 94.9% of Brukinsa patients were still alive without disease worsening, versus 84% of patients in the Imbruvica arm, translating into a preliminary risk reduction of 60%.
  • Brukinsa did demonstrate a clear safety edge in atrial fibrillation, with 2.5% of Brukinsa patients suffered atrial fibrillation, significantly lower than the 10.1% for the Imbruvica group.
  • 7.8% of Brukinsa patients stopped treatment because of side effects, compared with 13% of the Imbruvica group.
  • Price Action: BGNE shares are up 0.57% at $354.99 during the market session on the last check Friday.

Related Articles (JNJ + BGNE)

View Comments and Join the Discussion!

Posted-In: Briefs leukemiaBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at